Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

Bliss Gvs Pharma Limited

(NSE:BLISSGVS)

Select Model

Rating:72Outperform

Price Target:INR 720.00▲(11.04% Upside)

Action:reiterated

Date:08/20/26

The score is driven primarily by strong financial performance, led by a low-leverage balance sheet and improving recent profitability/free cash flow. Technicals add support due to a clear uptrend, but overbought signals temper the near-term outlook. Valuation is the key drag given the high P/E and low dividend yield.

Positive Factors

Revenue and earnings growthSustained revenue expansion and stronger recent net income indicate improving commercial scale and earnings capacity. If this trajectory continues, Bliss GVS Pharma should have a broader base from which to support product development, market expansion, and operating resilience over the coming quarters.

Negative Factors

Volatile profitabilityHistorical margin swings show that earnings power has not been consistently stable, even though the latest year improved. Such volatility can make future profit performance harder to forecast and may limit confidence that recent profitability will persist through changing operating conditions.

Bliss Gvs Pharma Limited (BLISSGVS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 68.85B
Dividend Yield: 0.23%
Average Volume (3M): 21.61K
Price to Earnings (P/E): 50.7
Beta (1Y): 1.03
Revenue Growth: 20.59%
EPS Growth: 27.16%
Country: India
Employees: 1,033
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an e...

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Strong overall fundamentals supported by a conservative, improving balance sheet (low and falling debt, rising assets/equity) and better recent profitability and free cash flow. The main offsets are historically volatile margins/earnings and choppy cash conversion, plus some operating-profitability clarity issues noted in the income statement analysis.

Income Statement

74Positive

Balance Sheet

88Very Positive

Cash Flow

69Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	10.05B	9.27B	8.10B	7.66B	7.47B	7.38B
Gross Profit	4.63B	5.02B	3.96B	2.49B	3.50B	3.47B
EBITDA	2.35B	2.35B	1.27B	1.49B	1.35B	762.38M
Net Income	1.36B	1.29B	842.99M	754.54M	708.59M	150.40M
Balance Sheet
Total Assets	0	14.92B	13.01B	12.14B	11.57B	11.09B
Cash, Cash Equivalents and Short-Term Investments	1.89B	1.89B	1.41B	1.41B	684.11M	1.35B
Total Debt	0	217.50M	881.04M	998.40M	1.02B	1.09B
Total Liabilities	-12.32B	2.61B	2.09B	2.11B	2.39B	2.62B
Stockholders Equity	12.32B	11.93B	10.50B	9.67B	8.84B	8.19B
Cash Flow
Free Cash Flow	483.04M	818.87M	298.48M	1.24B	-594.86M	614.77M
Operating Cash Flow	775.52M	1.39B	1.06B	1.52B	343.13M	1.35B
Investing Cash Flow	-272.20M	-382.80M	-754.41M	-1.33B	-77.51M	-929.75M
Financing Cash Flow	-448.06M	-892.11M	-303.45M	-208.93M	-249.38M	-237.30M

Bliss Gvs Pharma Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price648.40

Price Trends

50DMA654.32Negative

100DMA569.88Positive

200DMA406.46Positive

Market Momentum

MACD-2.56Positive

RSI49.15Neutral

STOCH75.98Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 648.40 is below the 20-day moving average (MA) of 653.98, below the 50-day MA of 654.32, and above the 200-day MA of 406.46, indicating a neutral trend. The MACD of -2.56 indicates Positive momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 75.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:BLISSGVS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:IOLCP	72Outperform	INR 52.17B	31.06	―	0.56%	18.56%	60.06%
IN:BLISSGVS	72Outperform	INR 68.94B	50.66	―	0.23%	20.59%	27.16%
IN:RPGLIFE	62Neutral	INR 42.54B	35.60	―	0.93%	11.78%	-34.54%
IN:INNOVACAP	60Neutral	INR 59.00B	38.10	―	0.19%	34.47%	20.42%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ORCHPHARMA	54Neutral	INR 49.89B	489.15	―	―	10.83%	-89.83%
IN:UNICHEMLAB	51Neutral	INR 34.04B	11.17	―	―	9.43%	132.94%

* General Sector Average

Performance Comparison

IN:BLISSGVS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:BLISSGVS	Bliss Gvs Pharma Limited	648.40	494.04	320.05%
IN:INNOVACAP	Innova Captab Limited	1031.10	221.75	27.40%
IN:IOLCP	IOL Chemicals & Pharmaceuticals Ltd.	177.75	84.69	91.01%
IN:ORCHPHARMA	Orchid Pharma Limited	833.05	64.40	8.38%
IN:RPGLIFE	RPG Life Sciences Limited	2572.40	160.58	6.66%
IN:UNICHEMLAB	Unichem Laboratories Limited	483.45	9.00	1.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 20, 2026

Bliss Gvs Pharma Limited AI Stock Analysis